Behcet Disease
17
4
4
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 17 trials
100.0%
+13.5% vs benchmark
18%
3 trials in Phase 3/4
38%
3 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (17)
Rheumatology Patient Registry and Biorepository
Turkish Adaptation of the VascuQoL-6 Quality of Life Scale
Cranial Nerve Functions in Behçet's Disease and Their Relationship With Clinical Parameters
EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
Quantification & Classification of Inflammatory Cells in Uveitis Using OCT
Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease
Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
Evaluation of Voice in Behcet's
Pilates Based Exercises in Patients With Behçet and Familial Mediterranean Fever.
Familial Mediterranean Fever and Behçet: Analysis Before and After Covid19 Pandemic
Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers
1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement
Role of Regulatory B Cells in Behçet's Disease
A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease
Phase III Study in Refractory Behcet's Disease
Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease